Related references
Note: Only part of the references are listed.Association of Long-term Antiseizure Medication Use and Incident Type 2 Diabetes Mellitus
Wei-En Johnny Tseng et al.
NEUROLOGY (2023)
Antiseizure medications and thyroid hormone homeostasis: Literature review and practical guideline
Anne Maria Rochtus et al.
EPILEPSIA (2022)
Stroke and Ischemic Heart Disease With Enzyme-inducing Antiseizure Medications: Time to Change Prescribing Habits
David G. Vossler
EPILEPSY CURRENTS (2022)
Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy
David Larsson et al.
JAMA NEUROLOGY (2022)
Association of Enzyme-Inducing Antiseizure Drug Use With Long-term Cardiovascular Disease
Colin B. Josephson et al.
JAMA NEUROLOGY (2021)
Cardiovascular disease risk, awareness, and treatment in people with epilepsy
Samuel W. Terman et al.
EPILEPSY & BEHAVIOR (2021)
Effects of long-term anti-seizure medication monotherapy on all-cause death in patients with post-stroke epilepsy: a nationwide population-based study in Taiwan
Chia-Yu Hsu et al.
BMC NEUROLOGY (2021)
Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice
Rodrigo Rocamora et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2020)
Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study
Eugen Trinka et al.
EPILEPSIA (2020)
Effects of lacosamide and carbamazepine on lipids in a randomized trial
Scott Mintzer et al.
EPILEPSIA (2020)
Enzyme-inducing antiseizure medication utilization in patients with epilepsy and vascular risk factors
Jonah Fox et al.
EPILEPSY & BEHAVIOR (2020)
Markers of bone and lipid metabolism with eslicarbazepine acetate monotherapy
Scott Mintzer et al.
EPILEPSY RESEARCH (2019)
Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study
Eugen Trinka et al.
EPILEPSIA (2018)
Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs
Scott Mintzer et al.
EPILEPSY RESEARCH (2018)
Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly
Scott Mintzer et al.
EPILEPSIA (2018)
EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure
V. Villanueva et al.
ACTA NEUROLOGICA SCANDINAVICA (2017)
Effects of eslicarbazepine acetate on lipid profile and sodium levels in patients with epilepsy
Patrizia Pulitano et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2017)
Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures
Graciana L. Galiana et al.
DRUGS IN R&D (2017)
Sodium Channel Blockers in the Treatment of Epilepsy
Martin J. Brodie
CNS DRUGS (2017)
Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate - Expert opinion
Jukka Peltola et al.
EPILEPSY & BEHAVIOR (2015)
Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests
M. Ley et al.
EPILEPSY RESEARCH (2015)
Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: A comparison with carbamazepine, oxcarbazepine and lacosamide
Simon Hebeisen et al.
NEUROPHARMACOLOGY (2015)
The consequences of refractory epilepsy and its treatment
Kenneth D. Laxer et al.
EPILEPSY & BEHAVIOR (2014)
Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study
V. Villanueva et al.
EPILEPSY RESEARCH (2014)
The effects of antiepileptic drugs on vascular risk factors: A narrative review
Niki Katsiki et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2014)
Enzyme induction with antiepileptic drugs: Cause for concern?
Martin J. Brodie et al.
EPILEPSIA (2013)
Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis
Yao-Chung Chuang et al.
EPILEPSIA (2012)
Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers
Jonathan Bullman et al.
EPILEPSIA (2011)
Should enzyme-inducing antiepileptic drugs be considered first-line agents?
Scott Mintzer et al.
EPILEPSIA (2009)
Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase
Russell A. DeBose-Boyd
CELL RESEARCH (2008)
Thyroid dysfunction associated with increased low-density lipoprotein cholesterol in epileptic children treated with carbamazepine monotherapy: A causal relationship?
Achilleas Attilakos et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2007)
Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy
Sherifa A. Hamed et al.
EPILEPSY RESEARCH (2007)
Eslicarbazepine acetate (BIA 2-093)
Luis Almeida et al.
NEUROTHERAPEUTICS (2007)
Clinical importance of the cytochromes P450
DW Nebert et al.
LANCET (2002)
Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels:: Comparison with carbamazepine
MJ Bonifácio et al.
EPILEPSIA (2001)
Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine
D Hainzl et al.
EPILEPSY RESEARCH (2001)
Share Paper
